Durable response to palbociclib and letrozole in ovarian cancer with CDKN2A loss

Alterations of the Retinoblastoma (Rb) pathway are frequent in ovarian cancer, typically resulting from CDKN2A down-regulation, CCNE1 amplification, CCND1/2 amplification, and RB1 loss. However, bi-allelic CDKN2A mutation or homozygous deletion is a very rare event, concerning less than 5% of patien...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Biol Ther
Main Authors: Frisone, Daniele, Charrier, Melinda, Clement, Sophie, Christinat, Yann, Thouvenin, Laure, Homicsko, Krisztian, Michielin, Olivier, Bodmer, Alexandre, Chappuis, Pierre O., McKee, Thomas A., Tsantoulis, Petros
Formato: Artigo
Idioma:Inglês
Publicado em: Taylor & Francis 2019
Assuntos:
Bedside-to-Bench Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7012162/
https://ncbi.nlm.nih.gov/pubmed/31709901
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384047.2019.1685291
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados